Psychedelics as Medicines: An Emerging New Paradigm
Clinical Pharmacology & Therapeutics November 4, 2016 De Nichols, Mw Johnson, Cd Nichols 366 citations
Serotonergic psychedelics like psilocybin and LSD, which activate 5-HT2A receptors, show preliminary efficacy in treating anxiety, depression, and addiction to tobacco and alcohol when combined with psychotherapy. Recent research suggests these compounds may also combat inflammatory diseases through novel mechanisms, potentially offering advantages over existing anti-inflammatory drugs. The authors propose that psychedelics work by temporarily destabilizing brain network hubs and global connectivity via amplified neuronal avalanches, allowing the brain to reset after acute effects subside. Anti-inflammatory effects could benefit both psychiatric and nonpsychiatric inflammation-related conditions, warranting rigorous further research.